CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: In the subgroup of patients on dasatinib, clonal lymphocytes increased, both CD8+ cytotoxic cells and NK- and gamma/delta T-cell fractions. These clones may help in the elimination of the residual CML cells.